YOLFTbeta
Galderma Group N

Galderma Group N

GALD · SW · Healthcare / Drug Manufacturers - Specialty & Generic

172.15CHF+0.30 (+0.17%)

Price History

Full chart

Market Stats

Previous Close171.85
Open174
Day Range169.4 – 174
52-Week Range134.41 – 188.25
Volume576.93K
Market Cap37.44B
P/E (TTM)52.81
Forward P/E30.21
EPS3.04
Dividend Yield0.22%
Beta-0.11
50-Day Avg167.64
200-Day Avg161.48

About

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Flemming Ornskov M.B.A., M.D., M.P.H.
  • Employees7.68K
  • HeadquartersZählerweg 10, Zug, Switzerland, 6300, Switzerland
  • Websitehttps://www.galderma.com

Leadership

  • Dr. Flemming Ornskov M.B.A., M.D., M.P.H.CEO & Director · b. 1958
  • Mr. Luigi Felice La CorteChief Financial Officer · b. 1969
  • Mr. Adrian MurphyHead of Global Operations · b. 1970
  • Mr. Emil IvanovHead of Strategy, Investor Relations & ESG
  • Ms. Nakisa Serry J.D., MBAGeneral Counsel, Chief Compliance Officer & Interim CHRO
  • Mr. Christian MarcouxChief Communications Officer
  • Ms. Desislava Lazarova M.D.Global Head of Customer Education & Training

Financials

Income Statement

Line item2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.42B3.88B4.29B4.89B5.24B
Cost of Revenue1.03B1.23B1.29B1.49B1.63B
Gross Profit2.38B2.65B2.99B3.40B3.61B
Operating Income329.04M353.58M536.00M710.20M829.00M
EBITDA520.60M640.35M851.00M1.06B1.22B
Net Income-154.27M-101.72M-56.23M254.35M642.16M
R&D342.53M326.21M301.31M286.28M254.56M
Interest Expense350.83M408.93M588.97M349.09M158.18M

Balance Sheet

Line item2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.53B12.42B12.26B12.62B13.39B
Total Liabilities7.99B7.95B6.98B4.83B5.24B
Total Equity4.53B4.47B5.28B7.79B8.15B
Cash283.48M233.98M361.53M457.00M780.00M
Total Debt5.67B5.66B4.83B2.76B2.75B
Net Debt5.38B5.42B4.46B2.30B1.97B

Cash Flow

Line item2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow195.66M114.93M165.00M429.77M1.19B
Investing Cash Flow-533.40M-76.21M-174.00M-287.10M-154.00M
Financing Cash Flow317.14M-74.45M142.00M-51.08M-728.00M
Capital Expenditure127.98M164.71M119.23M275.00M154.00M
Free Cash Flow67.69M-49.77M43.35M213.00M1.03B
Dividends Paid----41.00M

Earnings

Report DateJul 25, 2024Mar 5, 2025Jul 24, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Mar 4, 2027
EPS Estimate1.120.840.00-1.141.27-
EPS Actual0.550.770.821.41---
Surprise-50.89%-8.33%-----
Timing------Pre-market

Key Statistics & Ratios

Market Cap37.44B
Enterprise Value39.06B
Trailing P/E52.81
Forward P/E30.21
PEG Ratio1.18
Price / Sales6.32
Price / Book5.56
EPS3.04
Book Value29.48
Revenue (TTM)5.92B
Gross Profit (TTM)4.11B
EBITDA1.39B
Profit Margin14.57%
Operating Margin20.24%
Return on Equity10.83%
Return on Assets5.36%
Shares Outstanding233.19M
Shares Float131.27M
Beta-0.11
Dividend Yield0.22%
Dividend Rate0.35
Payout Ratio24.74%

Dividends

20261×
0.35Apr 24, 2026
20251×
0.15Apr 25, 2025